For investors

Unlocking Value by Building a Brighter Future

Welcome to the 'For Investors' section of our website


Corporate Information


Our focus on developing cutting-edge treatments for CNS and more specifically mental health and psychiatric disorders has garnered the attention of investors who share our commitment to improving the lives of patients. We believe that our approach to drug development and commercialisation is a solid strategy for unlocking value and building a brighter future.

We are a small but mighty team with a big vision: to make a meaningful impact on people's health. Our passion and commitment drives us to work tirelessly and creatively, leveraging our resources to find innovative solutions to some of the toughest healthcare challenges. We take pride in our ability to deliver real value to patients and to advance the state of the art in our field. Join us as we strive to build a brighter, healthier future for all.

Depression treatment, Psychiatric disease, Novel drugs

Neurentis: Revolutionising Neuroscience, Transforming Lives


Neurentis is a biotech company at the forefront of the neuroscience field, dedicated to developing innovative medicines for treating neuropsychiatric disorders. Our team of experts uses cutting-edge technology and a deep understanding of neuroscience to identify and develop new treatments.

Our approach involves targeting specific neural pathways and using a variety of techniques to modulate neural activity, with the goal of developing safe and effective drugs that can alleviate the symptoms of neuropsychiatric disorders.

We believe that our work has the potential to transform the lives of millions of people who are suffering from these debilitating conditions. By investing in Neurentis, you have the opportunity to join us on this mission to revolutionise neuroscience and improve the quality of life for people around the world.

Company Summary

Neurentis PLC is a UK based biotech company, specialising in the development of novel treatments for neurolo-psychiatric diseases. The Company’s portfolio includes a skin patch for the treatment of Treatment-Resistant Depression in late stage development, a formula we have designed with natural ingredients for those with mild symptoms and those who do not like to take drugs. We have strong Intellectual Property for our projects.

Management Team

The company is run by experienced ex-pharma industry executives, with more than 30 years’ experience in the sector each. The Board comprises of 3 Directors, the Chairman, the Chief Executive Officer and an Independent Non-Executive Director. Neurentis is supported by a diverse team of advisors and expert organisations with complementary expertise from the science, pharmaceutical and biotech industry.

Business Model

Our business model is to run a lean organisation, engaging top Contract Research Organisations for product development and collaborating with academic institutions and other companies. The company's team has a large network of contacts in the industry and is supported by financial and corporate advisors.

Company Strategy

Our core strategy centers on rigorous research and development, advancing novel neuroscience programs through critical early-stage milestones. This approach builds significant intellectual property value, creating attractive assets. We aim to maximize the impact of our scientific breakthroughs, aligning with industry trends that value innovative, de-risked assets for broader patient access.

Sector/Market Specialisation

According to the World Health Organization (WHO), depression is one of the major contributors to the global burden of disease. Approximately 350 million people had the condition as of 2015 and depression and anxiety, cost the global economy US$ 1 trillion each year. The part of the market with an even higher need is Treatment-Resistant Depression (TRD), the indication Neurentis is targeting. About 50-66% patients are suffering from TRD, that means they are resistant to first line therapy.

Route to Market

Neurentis’ route to market is via partnerships with established companies in its sector. These collaborations may cover selected territories or broader regions and typically involve royalties and milestone payments. By partnering, Neurentis avoids building a sales and marketing organisation and leverages the existing commercial infrastructure of larger pharma companies.

Pharma Market Potential

Global healthcare spending is expected to increase at an annual rate of 5.4% between 2017 to 2022, from USD 7.7 trillion to USD 10 trillion (Deloitte, 2019); among the major factors contributing to worldwide healthcare expenditures are ageing and growing populations, and the increasing prevalence of chronic diseases. Drugs achieve very quickly high sales and become global products because they are introduced in multiple markets by the companies that sell them which have an existing developed commercial infrastructure ready to introduce new products. Drugs can individually achieve sales of billions, much higher and faster than products in other industries.

Product Portfolio & Pipeline

Our portfolio includes:

  • NRNT-012302 (Quivara™), an advanced treatment for Treatment-Resistant Depression (TRD). Thsi is a transdermal patch formulation.
  • NRNT-012201 (Neurobiomod™), a Natural Formula containing ingredients which have shown promising results compared to antidepressants.
  • NRNT-042402, AI-Driven Drug Discovery. Utilising cutting-edge Artificial Intelligence to design a new drug with a best-in-class profile for depression.

    • Values

    Our fundamental values are of integrity alongside a desire to be honest and straightforward with one another. We are data-based and intellectually trustworthy while also recognising risks. We aspire to being leaders in our area of expertise, we have a clear vision of where we are going and focus our resources to achieve our objectives and strategies. We have a compelling desire to improve and to win in our sector We are a true partnership, ensuring we treat the company’s assets as our own while constantly having the company’s long term success in mind. We show respect for all, value differences and inspire achievement.

    Vision & Mission

    Our vision is to provide new medicines that improve the health of people suffering from serious diseases as well as the lives of their families and other carers. As a result of our vision and using our values, Neurentis will be successful in delivering true medical innovation around the world, together with its partners, and as a consequence be rewarded with leadership sales, profit and value creation, allowing our people, our shareholders and the various stakeholders to prosper. Innovation is the key to our business and we encourage outstanding Research & Development. We learn from both our successes and our failures; we work together with confidence and trust.

    Corporate Governance

    We understand that strong corporate governance is critical for building trust with our investors and other stakeholders. As a small company, we recognize that we may not have the same resources and procedures as larger companies, but we are committed to maintaining appropriate governance practices that are aligned with our size and stage of development. Our governance framework is designed to promote accountability, transparency, and ethical conduct across all aspects of our business. We have established a Board of Directors with diverse expertise and experience, and we regularly review and update our policies and procedures to ensure that they meet or exceed industry standards. We believe that our commitment to sound governance practices is essential for building long-term relationships with our investors and other stakeholders, and we will continue to prioritise this important aspect of our business as we grow and evolve in the years ahead.

    UN SDG principles

    Neurentis is dedicated to improving the lives of people who are suffering from neuropsychiatric disorders, and we believe that our work is closely aligned with several of the United Nations Sustainable Development Goals (SDGs). By developing innovative medicines to treat neuropsychiatric disorders, we are contributing to SDG 3, which aims to ensure healthy lives and promote well-being for all ages. In addition, our work has the potential to have a positive impact on SDG 10, which seeks to reduce inequalities within and among countries, by providing new treatment options for underserved patient populations. Finally, by promoting research and development in the field of neuroscience, we are also advancing SDG 9, which focuses on building resilient infrastructure, promoting inclusive and sustainable industrialization, and fostering innovation. Neurentis is proud to be part of a global community of companies and organizations that are working towards the achievement of the SDGs, and we remain committed to contributing to a more sustainable and equitable world through our work.

    Pioneering Mental Wellness: The Next Frontier in Neuroscience

    Why invest in Neurentis?

    Investing in Neurentis is a unique opportunity to be a part of a company that is dedicated to developing innovative solutions for neuropsychiatric disorders. With a strong focus on neuroscience and a cutting-edge treatment portfolio, Neurentis is poised to revolutionise the treatment outcome for people with mental health disorders. Our commitment to advancing the field and improving patient outcomes, coupled with a team of highly-skilled and dedicated professionals, make Neurentis an exciting investment choice for anyone looking to make a positive impact in the world of mental health. Join us in building a better future for those struggling with depression, mood disorders, and other mental health challenges.